Wei Wang, MD
Neurology · San Jose
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 32
- 8 carriers
- Office
- 1
Offices
1 location
Looking this up.
Hospitals listed: Good Samaritan Hospital · Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
32 plans · 8 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Wang’s office at (408) 216-8763 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
32 of 32 plans
| Alignment Health Advantage PPO (PPO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Astiva Health C-SNP WOW - NorCal (HMO C-SNP) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Premier Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Astiva Health Savings Plan - NorCal (HMO) | Astiva Health | Listed | Sep 27, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
| Central Health Classic Care Plan III (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Dual Access Plan (HMO D-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Embrace Care Plan (HMO C-SNP) | Central Health Medicare Plan | Listed, may be out of date | Sep 15, 2025 |
| Central Health Embrace Choice Plan (HMO C-SNP) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Central Health Valor Care Plan (HMO) | Central Health Medicare Plan | Listed | Aug 15, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A91418 · Current
Licensed to practise in California · since 2005 · expires 2027-01-31 · Anhwei Medical College Aka Anhui Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Good Samaritan HospitalSan Jose, CAAcute Care Hospital · Proprietary · Has an emergency department · Birthing-friendlyPart of HCA Healthcare, which runs 185 hospitals in 19 statesPatients rate it 2 of 5 · 67% would definitely recommend itOverall rating: 2 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0.337, Oct 2024 – Sep 2025
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Good Samaritan Hospital
Behind the star rating — Deaths: 0 better, 8 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 1 worse of 8 measures. Readmissions: 0 better, 5 the same, 4 worse of 9 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0.337 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.75 (0 to 1.67) · 1,340 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.84 (0.54 to 1.14) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 143.59 (98.7 to 188.49) · 98 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.7 · 45 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 7.1 · 100 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 12.7 · 270 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 11.3 · 573 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 15.6 · 820 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.5 · 482 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.3 · 3,711 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.12 (0 to 0.3) · 8,866 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.2 (0.01 to 0.38) · 9,051 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.65 (0.74 to 4.56) · 1,929 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.8 (0.21 to 3.39) · 670 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.33 (0.88 to 3.78) · 1,836 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 6.73 (0 to 13.46) · 669 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 7.58 (3.96 to 11.19) · 654 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.59 (0.13 to 3.04) · 496 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.27 (0 to 0.87) · 7,373 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 4.1 · 152 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 1.08 | No different | Oct 2024 – Sep 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.542 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.484 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 1.565 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 15.8 · 327 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 24.2 · 703 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 61.1 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 36.3 · 665 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 25.4 · 856 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 19 · 978 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 144 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 12.3 · 46 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 21.2 · 135 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.8 (10.1 to 18.6) · 129 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.2 (0.9 to 1.5) · 531 cases | No different | Jan 2024 – Dec 2024 |
What patients said (704 patients answered, 24% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 2 |
| Quietness | 1 |
| Recommend hospital | 3 |
| Room was "always" clean | 66% |
| Nurses "always" communicated well | 75% |
| Doctors "always" communicated well | 71% |
| Staff "always" explained | 54% |
| Yes, staff "did" give patients this information | 83% |
| Yes, staff "did" give patients information about help after discharge | 81% |
| Doctors "always" explained things so they could understand | 66% |
| Doctors "always" listened carefully | 69% |
| Doctors "always" treated them with courtesy and respect | 78% |
| Patients who gave a rating of "9" or "10" (high) | 63% |
| Staff "always" explained new medications | 68% |
| Nurses "always" explained things so they could understand | 69% |
| Nurses "always" listened carefully | 73% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 38% |
| "YES", patients would definitely recommend the hospital | 67% |
| Staff "always" explained possible side effects | 40% |
| Yes, staff "did" give patients information about possible symptoms | 86% |
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$283,261
Medicare paid this office $283,261 for 437 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $64,557 | $100 |
| Return visit (30+ min) | 209 | $53,548 | $115 |
| Critical care, first 30-74 minutes | 68 | $42,826 | $175 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 137 | $20,968 | $146 |
| Sleep study in sleep lab (6 years or older) | 32 | $20,250 | $633 |
See all 14 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $64,557 | $100 |
| Return visit (30+ min) | 209 | $53,548 | $115 |
| Critical care, first 30-74 minutes | 68 | $42,826 | $175 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 137 | $20,968 | $146 |
| Sleep study in sleep lab (6 years or older) | 32 | $20,250 | $633 |
| New patient visit (60+ min) | 99 | $18,717 | $189 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 24 | $15,828 | $660 |
| Long return visit (40+ min) | 39 | $9,246 | $162 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 249 | $7,612 | $14 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 52 | $4,119 | $74 |
| Nerve test | 14 | $3,751 | $268 |
| Therapy procedure using a positive pressure ventilator | 40 | $3,389 | $61 |
| Muscle electrical test | 15 | $2,717 | $94 |
| Critical care, each additional 30 minutes | 30 | $2,634 | $88 |
Who their Medicare patients are
437 Original Medicare patients in 2024. Average age 77 · Under 65 7% · 85 and older 22% · Women 51% · Also on Medicaid 33% · Health risk score 1.52. At or below the middle of the specialty; the typical neurology clinician is at 1.61.
Conditions among them: High blood pressure 75% · Stroke 44% · Diabetes 41% · Coronary heart disease 36% · Dementia 31% · Chronic kidney disease 28% · Atrial fibrillation 27% · Heart failure 22% · Depression 22% · Cancer 17% · COPD 13%.
The office billed $773,395, Medicare allowed $361,549 and paid $283,261; for 3,779 services of 21 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 437 | 3,779 | 77 | 1.52 | $773,395 | $283,261 |
| 2023 | 428 | 3,707 | 77 | 1.48 | $735,540 | $287,806 |
| 2022 | 471 | 2,447 | 77 | 1.58 | $749,571 | $276,350 |
| 2021 | 452 | 2,347 | 77 | 1.49 | $731,505 | $282,284 |
| 2020 | 450 | 3,093 | 77 | 1.67 | $717,275 | $258,551 |
| 2019 | 659 | 3,621 | 77 | 1.68 | $1,130,204 | $389,929 |
| 2018 | 672 | 6,569 | 77 | 1.74 | $1,248,910 | $435,200 |
| 2017 | 627 | 5,558 | 77 | 1.74 | $1,262,282 | $445,745 |
| 2016 | 598 | 3,912 | 76 | 1.70 | $1,201,070 | $421,939 |
| 2015 | 547 | 5,508 | 76 | 1.69 | $971,395 | $352,508 |
| 2014 | 467 | 7,479 | 76 | 1.52 | $878,580 | $321,563 |
| 2013 | 471 | 5,804 | 76 | 1.69 | $895,020 | $327,231 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 11 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 168 | $69,043 | $109 |
| Return visit (30+ min) | 177 | $54,321 | $122 |
| Critical care, first 30-74 minutes | 69 | $51,172 | $191 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 145 | $23,973 | $159 |
| New patient visit (60+ min) | 86 | $17,704 | $206 |
| Long return visit (40+ min) | 47 | $15,736 | $173 |
| Sleep study in sleep lab (6 years or older) | 19 | $12,593 | $663 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 17 | $11,783 | $693 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 53 | $4,533 | $80 |
| Critical care, each additional 30 minutes | 33 | $3,257 | $96 |
| Therapy procedure using a positive pressure ventilator | 25 | $2,350 | $64 |
2022: 12 services
| Return visit (30+ min) | 204 | $57,593 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 180 | $55,965 | $93 |
| Critical care, first 30-74 minutes | 75 | $51,203 | $193 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 180 | $33,318 | $179 |
| Long return visit (40+ min) | 54 | $18,513 | $171 |
| New patient visit (60+ min) | 72 | $14,757 | $205 |
| Sleep study in sleep lab (6 years or older) | 15 | $9,859 | $657 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 11 | $7,539 | $685 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 62 | $5,331 | $81 |
| Critical care, each additional 30 minutes | 38 | $3,693 | $97 |
| Muscle electrical test | 12 | $2,413 | $105 |
| Therapy procedure using a positive pressure ventilator | 21 | $1,522 | $63 |
2021: 11 services
| Critical care, first 30-74 minutes | 67 | $57,087 | $198 |
| Return visit (30+ min) | 192 | $52,819 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 153 | $50,788 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 158 | $29,995 | $184 |
| Long return visit (40+ min) | 66 | $25,239 | $173 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 24 | $17,572 | $703 |
| New patient visit (60+ min) | 73 | $15,463 | $212 |
| Sleep study in sleep lab (6 years or older) | 18 | $12,115 | $673 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 64 | $5,286 | $83 |
| Critical care, each additional 30 minutes | 38 | $3,883 | $100 |
| Therapy procedure using a positive pressure ventilator | 20 | $1,334 | $64 |
2020: 10 services
| Critical care, first 30-74 minutes | 59 | $56,828 | $201 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 149 | $44,483 | $97 |
| Return visit (30+ min) | 178 | $36,451 | $103 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 152 | $29,755 | $187 |
| Long return visit (40+ min) | 86 | $19,290 | $140 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 23 | $15,793 | $687 |
| New patient visit (60+ min) | 84 | $15,782 | $188 |
| Sleep study in sleep lab (6 years or older) | 17 | $10,983 | $646 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 63 | $5,667 | $83 |
| Critical care, each additional 30 minutes | 39 | $4,047 | $101 |
2019: 14 services
| Critical care, first 30-74 minutes | 124 | $81,282 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 257 | $72,315 | $93 |
| Return visit (30+ min) | 224 | $52,616 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 232 | $43,278 | $181 |
| New patient visit (60+ min) | 150 | $28,478 | $190 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 40 | $27,513 | $671 |
| Sleep study in sleep lab (6 years or older) | 38 | $24,020 | $632 |
| Long return visit (40+ min) | 84 | $13,872 | $133 |
| Muscle electrical test | 41 | $8,470 | $93 |
| Nerve test | 28 | $8,310 | $297 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 86 | $7,444 | $80 |
| Critical care, each additional 30 minutes | 43 | $4,505 | $102 |
| Nerve test | 14 | $3,029 | $216 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 13 | $847 | $65 |
2018: 15 services
| Critical care, first 30-74 minutes | 168 | $80,030 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 262 | $67,927 | $93 |
| Return visit (30+ min) | 250 | $60,654 | $101 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 194 | $36,020 | $182 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 51 | $35,008 | $686 |
| Sleep study in sleep lab (6 years or older) | 53 | $34,633 | $653 |
| New patient visit (60+ min) | 176 | $33,322 | $189 |
| Long return visit (40+ min) | 86 | $16,804 | $136 |
| Muscle electrical test | 51 | $9,890 | $90 |
| Nerve test | 24 | $7,414 | $297 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 14 | $5,938 | $424 |
| Nerve test | 25 | $5,762 | $230 |
| Critical care, each additional 30 minutes | 58 | $5,725 | $97 |
| Measurement of brain wave activity (eeg), awake and asleep | 81 | $4,643 | $53 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 22 | $1,438 | $65 |
2017: 16 services
| Critical care, first 30-74 minutes | 158 | $83,807 | $196 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 281 | $83,571 | $93 |
| Return visit (30+ min) | 237 | $58,750 | $99 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 45 | $35,733 | $674 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 181 | $33,720 | $181 |
| Sleep study in sleep lab (6 years or older) | 49 | $31,588 | $645 |
| New patient visit (60+ min) | 150 | $28,239 | $188 |
| Long return visit (40+ min) | 88 | $15,372 | $135 |
| Critical care, each additional 30 minutes | 147 | $14,855 | $98 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 34 | $13,773 | $394 |
| Muscle electrical test | 43 | $8,047 | $86 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 74 | $5,899 | $80 |
| Nerve test | 26 | $5,793 | $215 |
| Nerve test | 18 | $5,667 | $283 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 24 | $2,138 | $65 |
| Measurement of brain wave activity (eeg), awake and asleep | 23 | $1,327 | $53 |
2016: 15 services
| Critical care, first 30-74 minutes | 110 | $74,434 | $194 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 259 | $73,696 | $92 |
| Return visit (30+ min) | 226 | $49,787 | $99 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 229 | $42,566 | $180 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 44 | $35,827 | $676 |
| New patient visit (60+ min) | 175 | $32,641 | $187 |
| Sleep study in sleep lab (6 years or older) | 40 | $25,728 | $643 |
| Long return visit (40+ min) | 73 | $14,405 | $135 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 34 | $13,647 | $401 |
| Muscle electrical test | 65 | $12,174 | $89 |
| Critical care, each additional 30 minutes | 101 | $10,042 | $97 |
| Nerve test | 30 | $8,786 | $283 |
| Nerve test | 37 | $8,289 | $224 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 88 | $8,257 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 43 | $3,096 | $63 |
2015: 15 services
| Critical care, first 30-74 minutes | 87 | $61,077 | $191 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 209 | $54,111 | $91 |
| Return visit (30+ min) | 221 | $51,035 | $97 |
| New patient visit (60+ min) | 167 | $30,947 | $185 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 36 | $27,409 | $653 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 133 | $24,193 | $177 |
| Sleep study in sleep lab (6 years or older) | 35 | $21,819 | $623 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 33 | $15,831 | $480 |
| Muscle electrical test | 54 | $10,096 | $88 |
| Nerve test | 37 | $8,237 | $223 |
| Long return visit (40+ min) | 50 | $8,180 | $132 |
| Critical care, each additional 30 minutes | 65 | $6,330 | $96 |
| Nerve test | 20 | $5,560 | $278 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 55 | $4,798 | $63 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 47 | $4,109 | $82 |
2014: 16 services
| Critical care, first 30-74 minutes | 77 | $58,641 | $195 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 178 | $43,992 | $92 |
| Return visit (30+ min) | 175 | $42,723 | $98 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 136 | $25,002 | $180 |
| New patient visit (60+ min) | 124 | $23,131 | $187 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 25 | $19,176 | $661 |
| Sleep study in sleep lab (6 years or older) | 28 | $17,646 | $630 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 24 | $12,451 | $519 |
| Long return visit (40+ min) | 57 | $9,219 | $132 |
| Muscle electrical test | 53 | $9,142 | $88 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 71 | $8,775 | $64 |
| Nerve test | 30 | $6,479 | $216 |
| Nerve test | 20 | $5,586 | $279 |
| Critical care, each additional 30 minutes | 47 | $4,792 | $98 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 20 | $1,925 | $84 |
| Measurement of brain wave activity (eeg), awake and asleep | 22 | $1,462 | $52 |
2013: 14 services
| Critical care, first 30-74 minutes | 67 | $54,850 | $188 |
| Return visit (30+ min) | 198 | $50,594 | $98 |
| Sleep study in sleep lab with continuous airway pressure (6 years or older) | 40 | $31,055 | $690 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 163 | $29,835 | $89 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 154 | $27,369 | $175 |
| Sleep study in sleep lab (6 years or older) | 41 | $27,040 | $644 |
| New patient visit (60+ min) | 125 | $23,264 | $186 |
| Measurement of brain wave activity (eeg), 61-119 minutes | 29 | $16,002 | $533 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 115 | $14,290 | $62 |
| Muscle electrical test | 50 | $7,535 | $83 |
| Nerve test | 32 | $6,655 | $208 |
| Long return visit (40+ min) | 27 | $4,367 | $132 |
| Critical care, each additional 30 minutes | 42 | $4,012 | $96 |
| Measurement of brain wave activity (eeg), awake and asleep | 56 | $3,144 | $51 |
Medicaid work
$0 in 2022
Medicaid paid $0 for 25 billed services this clinician did in 2022, up to 24 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Short return visit (20+ min) | 25 | $0 |
| 2022 | 25 | 1 | 24 | $0 |
| 2021 | 114 | 3 | 61 | $0 |
| 2020 | 104 | 3 | 48 | $0 |
| 2019 | 177 | 5 | 84 | $0 |
| 2018 | 117 | 3 | 22 | $0 |
See the largest Medicaid services in earlier years
2021
| Arthrocentesis and injection of knee joint | 12 | $0 |
| Short return visit (20+ min) | 90 | $0 |
| Return visit (30+ min) | 12 | $0 |
2020
| Arthrocentesis and injection of knee joint | 12 | $0 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 14 | $0 |
| Short return visit (20+ min) | 78 | $0 |
2019
| Arthrocentesis and injection of knee joint | 19 | $0 |
| Glucose, blood by glucose monitoring device(s) cleared by the FDA specifically for home use | 20 | $0 |
| Short return visit (20+ min) | 93 | $0 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 13 | $0 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 32 | $0 |
2018
| Arthrocentesis and injection of knee joint | 24 | $0 |
| Short return visit (20+ min) | 47 | $0 |
| Hyaluronan or derivative, synvisc or synvisc-one, for intra-articular injection, 1 mg | 46 | $0 |
Drugs they prescribed that Part D paid
$67,116
Pharmacies billed $67,116 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 820) in 2024. At or below the middle of the specialty; the typical neurology clinician is at 0%.
791 generic and 29 brand-name prescriptions · $67,116 in drug cost · 16 antipsychotic prescriptions to people over 65.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Fycompa | 25 | $32,527 | $1,301 |
| Lacosamide | 26 | $5,530 | $213 |
| Levetiracetam | 152 | $4,324 | $28 |
| Carbidopa-Levodopa Er | 49 | $3,309 | $68 |
| Carbamazepine | 47 | $3,157 | $67 |
See all 22 drugs
| Fycompa | 25 | $32,527 | $1,301 |
| Lacosamide | 26 | $5,530 | $213 |
| Levetiracetam | 152 | $4,324 | $28 |
| Carbidopa-Levodopa Er | 49 | $3,309 | $68 |
| Carbamazepine | 47 | $3,157 | $67 |
| Memantine | 92 | $1,878 | $20 |
| Divalproex | 26 | $1,544 | $59 |
| Levetiracetam Er | 15 | $1,280 | $85 |
| Carbidopa-Levodopa | 14 | $1,251 | $89 |
| Sumatriptan | 16 | $1,146 | $72 |
| Gabapentin | 78 | $1,040 | $13 |
| Lamotrigine | 27 | $585 | $22 |
| Donepezil | 50 | $541 | $11 |
| Valproic Acid | 12 | $495 | $41 |
| Nortriptyline | 16 | $265 | $17 |
| Topiramate | 30 | $244 | $8 |
| Pregabalin | 12 | $174 | $15 |
| Quetiapine | 16 | $140 | $9 |
| Ropinirole | 12 | $116 | $10 |
| Clonazepam | 19 | $88 | $5 |
| Amitriptyline | 18 | $64 | $4 |
| Zolpidem | 12 | $29 | $2 |
Year by year
| 2024 | 820 | 150 | 0% (0) | 4% | $67,116 |
| 2023 | 734 | 115 | 0% (0) | 3% | $94,339 |
| 2022 | 686 | 129 | 0% (0) | None | $52,818 |
| 2021 | 550 | 115 | 0% (0) | None | $30,141 |
| 2020 | 513 | 123 | 0% (0) | None | $24,346 |
| 2019 | 604 | 131 | 0% (0) | None | $43,277 |
| 2018 | 766 | 123 | None | None | $43,596 |
| 2017 | 824 | 133 | None | None | $31,511 |
| 2016 | 672 | 118 | None | None | $36,441 |
| 2015 | 705 | 116 | 2% (17) | 12% | $63,077 |
| 2014 | 569 | 98 | 3% (17) | 15% | $51,757 |
| 2013 | 433 | 103 | None | 24% | $68,828 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 21 drugs
| Fycompa | 22 | $29,361 | $1,335 |
| Lacosamide | 36 | $23,463 | $652 |
| Levetiracetam | 120 | $5,215 | $43 |
| Levetiracetam Er | 14 | $5,066 | $362 |
| Carbamazepine | 55 | $4,580 | $83 |
| Divalproex | 34 | $4,287 | $126 |
| Zonisamide | 13 | $3,045 | $234 |
| Gabapentin | 86 | $2,924 | $34 |
| Carbidopa-Levodopa Er | 33 | $2,733 | $83 |
| Memantine | 58 | $2,410 | $42 |
| Carbidopa-Levodopa | 13 | $1,098 | $84 |
| Valproic Acid | 11 | $792 | $72 |
| Lamotrigine | 19 | $705 | $37 |
| Donepezil | 37 | $676 | $18 |
| Topiramate | 42 | $657 | $16 |
| Pregabalin | 11 | $633 | $58 |
| Amitriptyline | 20 | $441 | $22 |
| Sumatriptan | 11 | $354 | $32 |
| Nortriptyline | 21 | $185 | $9 |
| Quetiapine | 11 | $66 | $6 |
| Clonazepam | 11 | $65 | $6 |
2022: 17 drugs
| Memantine | 91 | $8,516 | $94 |
| Levetiracetam | 93 | $3,512 | $38 |
| Zonisamide | 13 | $2,850 | $219 |
| Gabapentin | 104 | $2,163 | $21 |
| Carbidopa-Levodopa Er | 33 | $2,085 | $63 |
| Quetiapine | 31 | $1,977 | $64 |
| Carbamazepine | 22 | $1,968 | $89 |
| Divalproex | 19 | $1,192 | $63 |
| Pregabalin | 16 | $876 | $55 |
| Baclofen | 13 | $804 | $62 |
| Topiramate | 27 | $414 | $15 |
| Carbidopa-Levodopa | 19 | $413 | $22 |
| Donepezil | 36 | $387 | $11 |
| Amitriptyline | 27 | $362 | $13 |
| Lamotrigine | 11 | $139 | $13 |
| Ropinirole | 11 | $81 | $7 |
| Prednisone | 11 | $61 | $6 |
2021: 13 drugs
| Memantine | 73 | $4,850 | $66 |
| Carbidopa-Levodopa Er | 18 | $2,614 | $145 |
| Carbidopa-Levodopa | 15 | $2,395 | $160 |
| Levetiracetam | 60 | $2,393 | $40 |
| Gabapentin | 89 | $1,571 | $18 |
| Quetiapine | 19 | $1,065 | $56 |
| Amitriptyline | 28 | $513 | $18 |
| Pregabalin | 12 | $471 | $39 |
| Donepezil | 46 | $408 | $9 |
| Topiramate | 17 | $394 | $23 |
| Rizatriptan | 13 | $299 | $23 |
| Nortriptyline | 15 | $171 | $11 |
| Zolpidem | 17 | $133 | $8 |
2020: 15 drugs
| Memantine | 44 | $2,019 | $46 |
| Levetiracetam | 47 | $1,846 | $39 |
| Carbidopa-Levodopa Er | 19 | $1,800 | $95 |
| Gabapentin | 110 | $1,567 | $14 |
| Carbamazepine | 15 | $1,308 | $87 |
| Carbidopa-Levodopa | 16 | $1,248 | $78 |
| Pregabalin | 21 | $1,092 | $52 |
| Amitriptyline | 25 | $758 | $30 |
| Topiramate | 19 | $591 | $31 |
| Quetiapine | 14 | $389 | $28 |
| Primidone | 14 | $253 | $18 |
| Donepezil | 27 | $253 | $9 |
| Ropinirole | 16 | $159 | $10 |
| Sumatriptan | 13 | $141 | $11 |
| Nortriptyline | 11 | $124 | $11 |
2019: 15 drugs
| Memantine | 61 | $5,178 | $85 |
| Lyrica | 11 | $4,148 | $377 |
| Carbidopa-Levodopa Er | 33 | $3,364 | $102 |
| Gabapentin | 115 | $3,093 | $27 |
| Levetiracetam | 45 | $1,678 | $37 |
| Carbidopa-Levodopa | 33 | $1,113 | $34 |
| Amitriptyline | 37 | $1,091 | $29 |
| Topiramate | 28 | $510 | $18 |
| Donepezil | 43 | $507 | $12 |
| Sumatriptan | 24 | $481 | $20 |
| Nortriptyline | 22 | $381 | $17 |
| Escitalopram | 18 | $304 | $17 |
| Ropinirole | 18 | $263 | $15 |
| Quetiapine | 12 | $232 | $19 |
| Prednisone | 16 | $125 | $8 |
2018: 19 drugs
| Memantine | 56 | $5,667 | $101 |
| Carbidopa-Levodopa Er | 57 | $3,783 | $66 |
| Gabapentin | 130 | $2,719 | $21 |
| Levetiracetam | 68 | $2,617 | $38 |
| Pyridostigmine | 11 | $1,346 | $122 |
| Carbamazepine | 20 | $1,269 | $63 |
| Carbidopa-Levodopa | 35 | $879 | $25 |
| Amitriptyline | 38 | $455 | $12 |
| Donepezil | 38 | $422 | $11 |
| Primidone | 14 | $386 | $28 |
| Ropinirole | 32 | $368 | $12 |
| Nortriptyline | 24 | $288 | $12 |
| Topiramate | 27 | $281 | $10 |
| Sumatriptan | 26 | $267 | $10 |
| Zolpidem | 20 | $200 | $10 |
| Escitalopram | 27 | $162 | $6 |
| Lamotrigine | 12 | $142 | $12 |
| Prednisone | 15 | $114 | $8 |
| Quetiapine | 14 | $113 | $8 |
2017: 19 drugs
| Namenda Xr | 19 | $9,045 | $476 |
| Gabapentin | 190 | $2,887 | $15 |
| Carbidopa-Levodopa Er | 61 | $2,395 | $39 |
| Levetiracetam | 79 | $2,345 | $30 |
| Memantine | 25 | $1,936 | $77 |
| Pyridostigmine | 17 | $1,556 | $92 |
| Zonisamide | 23 | $1,058 | $46 |
| Carbidopa-Levodopa | 60 | $1,015 | $17 |
| Ropinirole | 34 | $597 | $18 |
| Amitriptyline | 46 | $582 | $13 |
| Pramipexole Dihydrochloride | 12 | $577 | $48 |
| Topiramate | 27 | $301 | $11 |
| Sumatriptan | 25 | $284 | $11 |
| Prednisone | 17 | $137 | $8 |
| Quetiapine | 16 | $131 | $8 |
| Donepezil | 25 | $130 | $5 |
| Primidone | 20 | $127 | $6 |
| Zolpidem | 12 | $118 | $10 |
| Escitalopram | 13 | $52 | $4 |
2016: 16 drugs
| Namenda Xr | 39 | $16,523 | $424 |
| Carbidopa-Levodopa Er | 54 | $2,327 | $43 |
| Gabapentin | 118 | $1,800 | $15 |
| Pyridostigmine | 16 | $1,664 | $104 |
| Levetiracetam | 39 | $1,135 | $29 |
| Sumatriptan | 15 | $1,089 | $73 |
| Carbidopa-Levodopa | 55 | $994 | $18 |
| Memantine | 14 | $800 | $57 |
| Topiramate | 32 | $631 | $20 |
| Ropinirole | 39 | $582 | $15 |
| Amitriptyline | 29 | $449 | $15 |
| Donepezil | 46 | $393 | $9 |
| Quetiapine | 26 | $236 | $9 |
| Pramipexole Dihydrochloride | 15 | $214 | $14 |
| Lamotrigine | 16 | $186 | $12 |
| Primidone | 18 | $154 | $9 |
2015: 16 drugs
| Namenda Xr | 54 | $24,230 | $449 |
| Carbidopa-Levodopa Er | 53 | $3,253 | $61 |
| Gabapentin | 123 | $2,421 | $20 |
| Carbidopa-Levodopa | 70 | $1,465 | $21 |
| Pyridostigmine | 11 | $1,029 | $94 |
| Levetiracetam | 29 | $834 | $29 |
| Donepezil | 67 | $612 | $9 |
| Amitriptyline | 29 | $514 | $18 |
| Quetiapine | 36 | $400 | $11 |
| Nortriptyline | 14 | $304 | $22 |
| Butalb-Caff-Acetaminoph-Codein | 17 | $283 | $17 |
| Zolpidem | 12 | $265 | $22 |
| Topiramate | 28 | $233 | $8 |
| Primidone | 23 | $207 | $9 |
| Ropinirole | 16 | $198 | $12 |
| Sumatriptan | 16 | $158 | $10 |
2014: 16 drugs
| Namenda | 34 | $16,321 | $480 |
| Namenda Xr | 22 | $10,445 | $475 |
| Treximet | 11 | $7,554 | $687 |
| Gabapentin | 113 | $1,675 | $15 |
| Levetiracetam | 38 | $1,528 | $40 |
| Donepezil | 61 | $919 | $15 |
| Carbidopa-Levodopa Er | 24 | $887 | $37 |
| Quetiapine | 35 | $782 | $22 |
| Carbidopa-Levodopa | 26 | $677 | $26 |
| Primidone | 29 | $330 | $11 |
| Nortriptyline | 18 | $203 | $11 |
| Clonazepam | 14 | $176 | $13 |
| Butalb-Caff-Acetaminoph-Codein | 14 | $163 | $12 |
| Zolpidem | 17 | $148 | $9 |
| Amitriptyline | 26 | $121 | $5 |
| Topiramate | 11 | $97 | $9 |
2013: 13 drugs
| Namenda | 61 | $23,960 | $393 |
| Exelon | 16 | $4,927 | $308 |
| Levetiracetam | 43 | $1,708 | $40 |
| Gabapentin | 60 | $1,102 | $18 |
| Donepezil | 25 | $652 | $26 |
| Carbidopa-Levodopa | 15 | $633 | $42 |
| Escitalopram | 14 | $582 | $42 |
| Quetiapine | 26 | $441 | $17 |
| Clonazepam | 17 | $187 | $11 |
| Nortriptyline | 15 | $157 | $10 |
| Zolpidem | 20 | $142 | $7 |
| Topiramate | 13 | $133 | $10 |
| Amitriptyline | 21 | $69 | $3 |
Money from drug and device companies
$140 in 2024
| 2024 | 1 | 1 | None | $140 |
| 2022 | 1 | 1 | None | $16 |
| 2021 | 1 | 1 | None | $20 |
| 2019 | 1 | 1 | None | $17 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Mallinckrodt Hospital Products | Acthar | $140 | 1 payment
|
See the published payment
| Mallinckrodt Hospital Products | Meals · 2024-06-27 | Acthar | $140 |
See earlier years (2022, 2021, 2019)
2022: $16
| Genentech USA | Xofluza | $16 | 1 payment
|
2021: $20
| Genentech USA | Xofluza | $20 | 1 payment
|
2019: $17
| Ucb | Vimpat | $17 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 75.0 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1396704482
- Licence
- CA A91418, IN 01055906ACalifornia A91418: Current · expires 2027-01-31
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- IN 200374900
- Taxonomy
- Neurology (2084N0400X); Federal specialty code 2084S0012X (2084S0012X); Federal specialty code 2084V0102X (2084V0102X)
- Mailing address
- 2101 Forest Ave, Suite 221, San Jose, CA, 95128
- NPI first listed
- 2006-03-20
- NPI last updated
- 2008-11-25
This is when the NPI record was last certified, not a medical board exam.